Tanel Laisaar , Kadi Kallavus , Anneli Poola , Mari Räppo , Merily Taur , Vahur Makke , Marianna Frik , Pilvi Ilves , Kaja-Triin Laisaar
{"title":"基于人口的系统性个人登记确保肺癌筛查的高接受率","authors":"Tanel Laisaar , Kadi Kallavus , Anneli Poola , Mari Räppo , Merily Taur , Vahur Makke , Marianna Frik , Pilvi Ilves , Kaja-Triin Laisaar","doi":"10.1016/j.ctarc.2025.100889","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Lung cancer screening (LCS) is recommended by international societies, yet it is still debated how to efficiently enrol participants. The aim of this study was to evaluate systematic enrolment of patients through family physicians in a regional LCS pilot study in Estonia.</div></div><div><h3>Material and methods</h3><div>This study was conducted in one county (with approximately 10 % of the country's population), where all family physicians were approached. In each participating practice, all 55- to 74-year-old individuals were identified and evaluated by the family physician or nurse. Two LCS inclusion criteria were used in parallel – individuals with elevated lung cancer (LC) risk, according to either smoking status (≥20 pack-years; quit <15 years ago) and/or a PLCO<sub>m2012noRace</sub> risk score (>1.5 %/6 years), underwent low-dose computed tomography (LDCT). The scans were evaluated and participants managed according to LungRADS 1.1 protocol.</div></div><div><h3>Results</h3><div>Seventy-four participating family physician practices had 26 759 patients in the target age group. During the inclusion period 24 413 individuals were evaluated, of whom 17 215 were excluded. Of the remaining 7198 individuals, 3708 had higher LC risk and were referred for LDCT. Of the 3444 individuals who underwent LDCT, 30 were diagnosed with LC. Considering the total LCS target age group, an estimated participation rate of 79.3 % (95 %CI 78.1 %–80.5 %) was achieved.</div></div><div><h3>Conclusion</h3><div>Population-based systematic enrolment of participants for LCS by family physicians and nurses ensured very high uptake in the target group, providing a valuable reference for planning LCS programs in countries with family physicians on board.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100889"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Population-based systematic enrolment of individuals ensures high lung cancer screening uptake\",\"authors\":\"Tanel Laisaar , Kadi Kallavus , Anneli Poola , Mari Räppo , Merily Taur , Vahur Makke , Marianna Frik , Pilvi Ilves , Kaja-Triin Laisaar\",\"doi\":\"10.1016/j.ctarc.2025.100889\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Lung cancer screening (LCS) is recommended by international societies, yet it is still debated how to efficiently enrol participants. The aim of this study was to evaluate systematic enrolment of patients through family physicians in a regional LCS pilot study in Estonia.</div></div><div><h3>Material and methods</h3><div>This study was conducted in one county (with approximately 10 % of the country's population), where all family physicians were approached. In each participating practice, all 55- to 74-year-old individuals were identified and evaluated by the family physician or nurse. Two LCS inclusion criteria were used in parallel – individuals with elevated lung cancer (LC) risk, according to either smoking status (≥20 pack-years; quit <15 years ago) and/or a PLCO<sub>m2012noRace</sub> risk score (>1.5 %/6 years), underwent low-dose computed tomography (LDCT). The scans were evaluated and participants managed according to LungRADS 1.1 protocol.</div></div><div><h3>Results</h3><div>Seventy-four participating family physician practices had 26 759 patients in the target age group. During the inclusion period 24 413 individuals were evaluated, of whom 17 215 were excluded. Of the remaining 7198 individuals, 3708 had higher LC risk and were referred for LDCT. Of the 3444 individuals who underwent LDCT, 30 were diagnosed with LC. Considering the total LCS target age group, an estimated participation rate of 79.3 % (95 %CI 78.1 %–80.5 %) was achieved.</div></div><div><h3>Conclusion</h3><div>Population-based systematic enrolment of participants for LCS by family physicians and nurses ensured very high uptake in the target group, providing a valuable reference for planning LCS programs in countries with family physicians on board.</div></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":\"43 \",\"pages\":\"Article 100889\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294225000279\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Population-based systematic enrolment of individuals ensures high lung cancer screening uptake
Introduction
Lung cancer screening (LCS) is recommended by international societies, yet it is still debated how to efficiently enrol participants. The aim of this study was to evaluate systematic enrolment of patients through family physicians in a regional LCS pilot study in Estonia.
Material and methods
This study was conducted in one county (with approximately 10 % of the country's population), where all family physicians were approached. In each participating practice, all 55- to 74-year-old individuals were identified and evaluated by the family physician or nurse. Two LCS inclusion criteria were used in parallel – individuals with elevated lung cancer (LC) risk, according to either smoking status (≥20 pack-years; quit <15 years ago) and/or a PLCOm2012noRace risk score (>1.5 %/6 years), underwent low-dose computed tomography (LDCT). The scans were evaluated and participants managed according to LungRADS 1.1 protocol.
Results
Seventy-four participating family physician practices had 26 759 patients in the target age group. During the inclusion period 24 413 individuals were evaluated, of whom 17 215 were excluded. Of the remaining 7198 individuals, 3708 had higher LC risk and were referred for LDCT. Of the 3444 individuals who underwent LDCT, 30 were diagnosed with LC. Considering the total LCS target age group, an estimated participation rate of 79.3 % (95 %CI 78.1 %–80.5 %) was achieved.
Conclusion
Population-based systematic enrolment of participants for LCS by family physicians and nurses ensured very high uptake in the target group, providing a valuable reference for planning LCS programs in countries with family physicians on board.
期刊介绍:
Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.